Vytorin

Source: news.google.com --- 33 days ago
E Canada Now Vytorin Study's Ethical Morass Forbes - 2 hours ago Cardiologists and statisticians are arguing about whether the cholesterol drug Vytorin might increase the rate of cancer deaths. But experts on both sides of the argument agree on one thing: They don’t like the way the results were made public. Medical Journal Raises Concern About Vytorin Wall Street Journal Editors warn: Don't 'just brush aside' Vytorin-cancer link USA Today New York Times  - Washington Post  - dBTechno  - WebMD all 464 news articles ...

Source: news.google.com --- 31 days ago
Canada.com Many Questions About Vytorin New York Times - 28 minutes ago The risks and benefits of a best-selling anti-cholesterol drug remain thoroughly muddled despite a new analysis that purports to exonerate it from the worst safety concerns. House committee widens probe of Vytorin safety International Herald Tribune Drug Scare Shenanigans FOXNews Reuters  - Forbes  - U.S. News & World Report  - Wall Street Journal all 542 news articles ...

Source: news.google.com --- 32 days ago
ChattahBox Flash: Vytorin Study Not A Conspiracy Forbes - 1 hour ago There's plenty of controversy right now concerning the SEAS study of Vytorin, and whether or not the available data support a link between the drug and cancer death. Vytorin may hold up long term despite recent woes Reuters Health Buzz: More Vytorin Studies and Other Health News U.S. News & World Report New York Times  - eFluxMedia  - Wall Street Journal  - USA Today all 519 news articles ...

Source: news.google.com --- 32 days ago
Canada.com Vytorin Cancer Risk 'Not Ruled Out Forbes - 2 hours ago One of the most prominent statisticians in the US is taking issue with an analysis that claims there is no credible evidence the cholesterol drug Vytorin increases the risk of cancer death. Vytorin may hold up long term despite recent woes Reuters Health Buzz: More Vytorin Studies and Other Health News U.S. News & World Report PharmExec.com  - TheStreet.com  - New York Times  - Wall Street Journal all 508 news articles ...

Source: www.iht.com --- 31 days ago
A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers. ...

Source: www.cnn.com --- 30 days ago
Read full story for latest details. ...

Source: www.nytimes.com --- 31 days ago
The F.D.A. needs to evaluate whether it should demand larger and more definitive clinical trials before approving certain drugs. ...

Source: www.moreover.com --- 2 days ago
Extract not available. ...

Source: www.marketwatch.com --- 3 days ago
LONDON (MarketWatch) -- Merrill Lynch cut its rating on Schering-Plough to underperform from neutral and lowered its price target to $18 from $22, saying it expects the efficacy and safety controversies around Vytorin/Zetia to continue. In addition, the broker told clients that the drugmaker has the greatest currency risk of U.S. peers. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news. ...

Source: online.wsj.com --- 33 days ago
NEJM editors said that it is too soon to dismiss concerns about cancer risks linked to the popular cholesterol drug Vytorin, even as the journal published a report saying a previously reported cancer link was likely due to chance. ...

Source: www.forbes.com --- 33 days ago
New questions are raised about the boundaries between science and commerce. ...

Source: www.forbes.com --- 32 days ago
Statistician Thomas Fleming of the University of Washington says a key analysis was improper. ...

Source: www.newsday.com --- 32 days ago
MUNICH, German -- Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday. ...

Source: www.baltimoresun.com --- 33 days ago
Medical journal addresses effectiveness, possible cancer link of highly popular drugs New research into a possible link between a cholesterol-reducing drug and cancer concluded there was no proof to establish a connection, but other doctors warned that it should be used more carefully. ...

Source: www.medscape.com --- 33 days ago
The SEAS data were presented today at the European Society of Cardiology, but the focus turned to the cancer risks observed in the trial. An analysis of ongoing studies--IMPROVE-IT and SHARP--suggests the finding is a play of chance, but others, including prominent New England Journal of Medicine editorialists, say there is uncertainty about the safety and efficacy of the drug. Heartwire ...

Source: www.moreover.com --- 33 days ago
C-Health Sep 3 2008 3:19AM GMT ...

Source: www.moreover.com --- 33 days ago
Find Law Sep 3 2008 6:49AM GMT ...

Source: www.postchronicle.com --- 32 days ago
Researchers reported last month that patients in three clinical trials had a 40 percent higher chance of dying of cancer if they took Vytorin instead of a placebo...... ...

Source: cbs2chicago.com --- 32 days ago
Results from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with great caution until more is known, editors of a leading medical journal urged Tuesday. ...